Pokorska-Śpiewak Maria, Dobrzeniecka Anna, Ogrodnik Agnieszka
Department of Children's Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, Poland.
Regional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland.
Infect Dis Rep. 2022 Aug 3;14(4):574-578. doi: 10.3390/idr14040061.
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5-10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings.
本文介绍了索磷布韦/维帕他韦对3名5至10岁患者进行12周治疗的疗效和安全性。所有3名儿童都患有合并症，其中两名患有慢性肾病。所有参与者在治疗结束12周后均实现了持续病毒学应答。治疗期间及之后均未报告不良反应，且依从性良好。对于6岁以下儿童开始治疗的决策应个体化，并考虑依从性。幼儿在治疗期间需要调整药物制剂和剂量。需要对更多患者群体进行进一步研究以证实我们的发现。
